XTALPI

XtalPi started in a lab, not a garage. Three physicists, Shuhao Wen, Jian Ma, and Lipeng Lai, met at MIT.

They were trained in quantum physics, the math that describes how atoms and molecules actually behave. They had an idea.

Use that physics, plus AI, to predict how a drug molecule will form and behave before anyone makes it in a lab. Drug discovery is famously slow.

It can take years and billions of dollars to find one molecule that works. XtalPi launched in 2015 to compress that with computers.

Google was an early backer, which got the company noticed fast.

XtalPi makes money two ways. First, it sells research services to big drug and materials companies.

A pharma company hires XtalPi to run AI and quantum simulations, then test the promising molecules in XtalPi's automated labs. Think of it as renting a very fast research team that mixes software and robots.

Second, it builds its own drug and materials projects and sometimes shares in the upside if they succeed. The pitch is simple.

Computers narrow millions of options down to a few, then robots test those few without humans slowing things down.

XtalPi's core is a platform that fuses AI, quantum physics, and automated labs. The software predicts how molecules will behave.

The robotic labs then synthesize and test the top candidates without waiting on human schedules. It serves drug discovery, where it helps design new medicines, and materials science, where it helps design things like better battery and chemical compounds.

The product is really a faster, cheaper way to run the early, expensive part of research.

XtalPi leaned on two things. Heavyweight backers and automated labs.

Early money from Google, Tencent, and Sequoia China gave it credibility and cash most startups never see. It used that to build robotic labs in Shenzhen, Shanghai, and Boston that run experiments day and night.

It also landed big-name customers, including research deals with major pharma partners worth large sums if the projects hit. The 2024 Hong Kong IPO was the next step.

It listed as the first company under HKEX rules designed for tech firms that are not yet profitable.

XtalPi has a money problem. It is not profitable, and AI drug discovery is full of promises that have not paid off yet.

No company has proven that AI can reliably turn out blockbuster drugs faster than the old way. XtalPi sells services and shares in projects, but the giant payday only comes if one of those drugs actually reaches the market.

That takes years. The company also straddles the US and China at a tense moment for both.

Investors love the story. They are still waiting on the profit.

XtalPi raised about $732 million in private funding before going public. Google was an early backer, alongside Tencent and Sequoia China, which gave the company instant credibility in 2017.

SoftBank's Vision Fund 2 led a roughly $319 million Series C in 2020. A Series D in 2021 reportedly raised around $380 million and valued XtalPi near $2 billion.

In June 2024 it raised about $115 million in a Hong Kong IPO, becoming the first company to list under the exchange's Chapter 18C rules for specialist tech companies.